IceCure Medical Ltd (ICCM) Financial Ratios
12 years of historical data (2014–2025) · Healthcare · Medical - Devices
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
1.07
↓-76% vs avg
5yr avg: 4.38
30Y Low2.3·High8.1
ROE
↓
-188.8%
↑-69% vs avg
5yr avg: -111.4%
30Y Low-312%·High-64%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ICCM Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
IceCure Medical Ltd currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $10M | $39M | $56M | $49M | $57M | $87M | — | — | — | — | — |
| Enterprise Value | $2M | $30M | $49M | $39M | $34M | $62M | — | — | — | — | — |
| P/E Ratio → | -0.63 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 3.02 | 11.48 | 17.01 | 15.12 | 18.60 | 21.04 | — | — | — | — | — |
| P/B Ratio | 1.07 | 4.28 | 8.11 | 4.01 | 2.26 | 3.23 | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
ICCM EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 8.91 | 14.85 | 12.05 | 11.12 | 15.07 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
ICCM Profitability
Margins and return-on-capital ratios measuring operating efficiency
IceCure Medical Ltd earns an operating margin of -446.7%. Operating margins have expanded from -482.4% to -446.7% over the past 3 years, signaling improving operational efficiency. A negative ROE of -188.8% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 36.3% | 36.3% | 44.1% | 40.3% | 46.8% | 53.0% | 65.1% | 34.8% | 41.9% | 25.4% | 35.4% |
| Operating Margin | -446.7% | -446.7% | -476.9% | -482.4% | -542.6% | -235.0% | -106.8% | -278.0% | -295.8% | -386.6% | -496.2% |
| Net Profit Margin | -445.6% | -445.6% | -465.5% | -453.8% | -558.1% | -243.3% | -117.0% | -287.2% | -329.7% | -417.2% | -522.8% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -188.8% | -188.8% | -160.7% | -78.0% | -65.7% | -63.8% | -132.5% | -158.9% | -227.3% | -311.6% | -109.9% |
| ROA | -113.8% | -113.8% | -105.7% | -62.9% | -55.1% | -47.2% | -54.1% | -75.7% | -98.4% | -109.7% | -78.2% |
| ROIC | -13557.5% | -13557.5% | -1162.7% | -509.1% | -545.1% | -402.0% | -236.6% | — | — | — | — |
| ROCE | -187.2% | -187.2% | -160.2% | -81.1% | -61.9% | -56.1% | -86.2% | -118.5% | -142.4% | -170.8% | -86.7% |
ICCM Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $9M exceeds total debt of $217000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.07 | 0.05 | 0.02 | 0.03 | 0.07 | 0.09 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.96 | -1.03 | -0.82 | -0.91 | -0.92 | -0.70 | -2.11 | -1.25 | — | -1.34 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -70.04 | -56.87 | -107.10 | -208.26 | -47.44 | -46.07 | -21.11 |
Net cash position: cash ($9M) exceeds total debt ($217000)
ICCM Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
IceCure Medical Ltd's current ratio of 2.61x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 2.07x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 3.66x to 2.61x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.61 | 2.61 | 1.95 | 3.66 | 6.49 | 7.54 | 2.48 | 1.90 | 4.42 | 1.18 | 5.79 |
| Quick Ratio | 2.07 | 2.07 | 1.59 | 3.08 | 5.83 | 7.06 | 2.18 | 1.70 | 3.86 | 0.99 | 5.22 |
| Cash Ratio | 1.84 | 1.84 | 1.37 | 2.86 | 5.46 | 6.37 | 0.90 | 1.59 | 3.59 | 0.93 | 5.06 |
| Asset Turnover | — | 0.24 | 0.26 | 0.20 | 0.10 | 0.13 | 0.40 | 0.23 | 0.20 | 0.36 | 0.19 |
| Inventory Turnover | 0.82 | 0.82 | 0.93 | 0.85 | 0.57 | 0.99 | 1.25 | 1.51 | 0.95 | 1.71 | 1.26 |
| Days Sales Outstanding | — | 35.75 | 24.51 | 11.64 | 43.30 | 68.01 | 14.74 | 0.00 | 85.26 | 0.00 | 38.38 |
ICCM Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
IceCure Medical Ltd does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — |
| Shares Outstanding | — | $64M | $51M | $46M | $37M | $29M | $17M | $14M | $12M | $6M | $5M |
Peer Comparison
Compare ICCM with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ICCMYou | $10M | -0.6 | — | — | 36.3% | -446.7% | -188.8% | -13557.5% | — |
 NVCR | $2B | -13.2 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 XTNT | $65M | 15.3 | 6.1 | 6.3 | 62.9% | 5.4% | 10.6% | 8.1% | 2.3 |
 ATEC | $1B | -8.0 | 3727.7 | 418.7 | 69.6% | -10.7% | -630.7% | -12.6% | 1425.2 |
 HALO | $8B | 27.3 | 11.4 | 12.8 | 78.1% | 58.4% | 153.6% | 32.1% | 2.4 |
 ISRG | $145B | 51.8 | 39.1 | 58.1 | 66.0% | 29.3% | 16.6% | 15.0% | 0.1 |
 BSX | $71B | 24.6 | 21.8 | 19.4 | 69.0% | 19.8% | 12.4% | 8.8% | 3.3 |
 MDT | $100B | 21.6 | 14.3 | 19.3 | 65.3% | 17.8% | 9.4% | 6.0% | 3.2 |
 ABT | $151B | 11.4 | 15.8 | 23.8 | 50.8% | 16.3% | 30.9% | 9.9% | 1.5 |
 SYK | $113B | 35.1 | 20.4 | 26.4 | 64.0% | 19.5% | 15.1% | 11.4% | 2.4 |
 ZBH | $17B | 23.9 | 9.6 | 11.3 | 61.6% | 16.5% | 5.6% | 5.4% | 3.1 |
| Healthcare Median | — | 22.2 | 13.9 | 18.2 | 64.0% | -4.2% | -32.4% | -11.1% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 12 years · Updated daily
What if you invested $1,000 in ICCM 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in ICCM be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs ICCM Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationICCM vs NVCR — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs NovoCure Limited.
Compare NowICCM — Frequently Asked Questions
Quick answers to the most common questions about buying ICCM stock.
What is IceCure Medical Ltd's P/E ratio?
IceCure Medical Ltd's current P/E ratio is -0.6x. This places it at the 50th percentile of its historical range.
What is IceCure Medical Ltd's ROE?
IceCure Medical Ltd's return on equity (ROE) is -188.8%. The historical average is -157.1%.
Is ICCM stock overvalued?
Based on historical data, IceCure Medical Ltd is trading at a P/E of -0.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are IceCure Medical Ltd's profit margins?
IceCure Medical Ltd has 36.3% gross margin and -446.7% operating margin.